Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease
Year: 2019
Type: article
Study design: Observational Study
Abstract: Non-alcoholic fatty liver disease (NAFLD) affects 25% of the population and can progress to cirrhosis with limited treatment options. As the liver secretes most of the blood plasma proteins, liver disease may affect the plasma proteome. Plasma proteome profiling of 48 patients with and without cirrhosis or NAFLD revealed six statistically significantly changing proteins (ALDOB, APOM, LGALS3BP, PIGR, VTN, and AFM), two of which are already linked to liver disease. Polymeric immunoglobulin receptor (PIGR) was significantly elevated in both cohorts by 170% in NAFLD and 298% in cirrhosis and was further validated in mouse models. Furthermore, a global correlation map of clinical and proteomic data strongly associated DPP4, ANPEP, TGFBI, PIGR, and APOE with NAFLD and cirrhosis. The prominent diabetic drug target DPP4 is an aminopeptidase like ANPEP, ENPEP, and LAP3, all of which are up-regulated in the human or mouse data. Furthermore, ANPEP and TGFBI have potential roles in extracellular matrix remodeling in fibrosis. Thus, plasma proteome profiling can identify potential biomarkers and drug targets in liver disease.
Source: Molecular Systems Biology
Institutions: University of Copenhagen, Novo Nordisk Foundation, Max Planck Institute of Biochemistry, Rigshospitalet, Novo Nordisk Foundation Center for Basic Metabolic Research, Hvidovre Hospital, Gentofte Hospital, Steno Diabetes Center Copenhagen, Helmholtz Munich, Technical University of Munich, LMU Klinikum, German Center for Diabetes Research, Ludwig-Maximilians-Universität München
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: non-alcoholic fatty liver disease, liver cirrhosis, plasma proteome, polymeric immunoglobulin receptor, ANPEP, dipeptidyl peptidase IV, TGFBI, apolipoprotein E, aldolase B, apolipoprotein M, LGALS3BP, vitronectin, extracellular matrix remodeling, liver fibrosis, biomarkers, therapeutic target, mouse model
Open Access status: gold
Estimated APC paid: $4,200
OpenAlex ID: W2919811956
